Lion TCR Clinched 'Most Promising Cell & Gene Therapy Startup in Asia' Award
Lion TCR Pte Ltd, clinical-stage biotech company specialized in the development and commercialization of its proprietary engineered T Cell Receptor (TCR) products against infectious disease and its associated cancers, has been recognized as the ‘Most Promising Cell & Gene Therapy Startup in Asia’ category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022, organized by IMAPAC.
Antonio Bertoletti Karolinska Institute Singapore Agency For Science Stanford University Research Development Pte Ltd
Source: biospace.com